MIF and metabolic dysfunction-associated steatotic liver disease: Nevertheless, given the body of evidence presented, we speculate that small molecule MIF inhibitors may have therapeutic potential to ameliorate obesity-induced IR, halting the progression to T2D and non-alcoholic fatty liver disease.